Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
The rationale for treating allergic asthma with anti-IgE Source: Eur Respir Rev 2007; 16: 61-66 Year: 2007
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001
Omalizumab inhibits allergen challenge-induced nasal response Source: Eur Respir J 2004; 23: 414-419 Year: 2004
Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
The specific methods of immunotherapy in treatment of the patients with allergic seasonal rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
The effect of smoking on the response to nasal antigen challenge in patients with allergic rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 217s Year: 2002
Local cytokine profile specifics among patients with BA phenotype, associated to allergic rhinitis: allergic rhinitis and bronchial asthma. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018
The role of omalizumab or rhuMAb-E25 in the treatment of allergic rhinitis Source: Eur Respir J 2004; 24: 330 Year: 2004
Allergen-specific IgE patterns in allergic diseases of respiratory system with atopic dermatitis. Source: International Congress 2019 – Asthma and allergies worldwide Year: 2019
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002
Specific serum IgE is associated with seasonal symptom load in children with allergic rhinitis Source: Annual Congress 2008 - Risk factors for allergic asthma and allergic rhinitis Year: 2008
The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma Year: 2008
Does allergens influence resistin levels in children with allergic rhinitis? Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Immunotherapy prevents the development of asthma in subjects with allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001
The role of T-lymphocytes in food allergy and asthma Source: Annual Congress 2005 - Food allergy, atopic dermatitis and asthma Year: 2005